UPDATE: Connect Biopharma's Interim Topline Data from Phase 2 Study Shows Rademikibart Reduced Treatment Failure Rate At 28 Days By 66% (Though This Endpoint Did Not Reach Statistical Significance) And Improved Lung Function Vs. Placebo

Loading news article.

UPDATE: Connect Biopharma's Interim Topline Data from Phase 2 Study Shows Rademikibart Reduced Treatment Failure Rate At 28 Days By 66% (Though This Endpoint Did Not Reach Statistical Significance) And Improved Lung Function Vs. Placebo | WAPE

UPDATE: Connect Biopharma's Interim Topline Data from Phase 2 Study Shows Rademikibart Reduced Treatment Failure Rate At 28 Days By 66% (Though This Endpoint Did Not Reach Statistical Significance) And Improved Lung Function Vs. Placebo

Article summary

Related companies

Analyzed by WAPE AI.

Comments —